US OptionsDetailed Quotes
MREO240920C6000
- 0.24
- 0.000.00%
15min DelayClose Aug 23 16:00 ET
0.44High0.05Low
0.25Open0.24Pre Close215 Volume352 Open Interest6.00Strike Price5.03KTurnover110.86%IV29.19%PremiumSep 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.24Extrinsic Value100Contract SizeAmericanOptions Type0.2877Delta0.2352Gamma21.47Leverage Ratio-0.0094Theta0.0009Rho6.18Eff Leverage0.0045Vega
Mereo BioPharma Stock Discussion
Sign in to post a comment
Double top right now in the 4.40 area. If that doesn't get broken then watch for a pull back. Here are the macro levels to keep an eye on if you are looking for an entry long.
Larger Image: tradingview.com...
$Mereo BioPharma (MREO.US)$
Larger Image: tradingview.com...
$Mereo BioPharma (MREO.US)$
2
1
$Mereo BioPharma (MREO.US)$
Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy
Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy
$SPDR S&P Biotech ETF (XBI.US)$
$Merck & Co (MRK.US)$ x $Immunovant (IMVT.US)$
$Eli Lilly and Co (LLY.US)$ x $Cytokinetics (CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals (REGN.US)$ x $Apellis Pharmaceuticals (APLS.US)$ (panache & brash)
$Gilead Sciences (GILD.US)$ x % $Madrigal Pharmaceuticals (MDGL.US)$ (liver king)
$Bristol-Myers Squibb (BMY.US)$ x $Iovance Biotherapeutics (IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co (LLY.US)$ x $Merus (MRUS.US)$ (partner n...
$Merck & Co (MRK.US)$ x $Immunovant (IMVT.US)$
$Eli Lilly and Co (LLY.US)$ x $Cytokinetics (CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals (REGN.US)$ x $Apellis Pharmaceuticals (APLS.US)$ (panache & brash)
$Gilead Sciences (GILD.US)$ x % $Madrigal Pharmaceuticals (MDGL.US)$ (liver king)
$Bristol-Myers Squibb (BMY.US)$ x $Iovance Biotherapeutics (IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co (LLY.US)$ x $Merus (MRUS.US)$ (partner n...
4
$SPDR S&P Biotech ETF (XBI.US)$
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
14
1
$Mereo BioPharma (MREO.US)$ LFG!!!!
1
1
No comment yet
Paul Anthony : tq Sir God bless All you need